Charles River Laboratories International, Inc. (CRL), based in Wilmington, Massachusetts, has a market capitalization of approximately $14 billion. The company is a global contract research organization that supports pharmaceutical, biotechnology, and medical device companies. It provides research, drug discovery, safety assessment, microbial solutions, and biologics services to help develop medicines and therapies.
Companies valued between $10 billion and $200 billion are generally classified as “large-cap stocks,” and Charles River Laboratories comfortably fits this category. Its substantial market capitalization reflects its size, influence and established presence in the diagnostics and research industry. Charles River Laboratories stands at the intersection of drug discovery and development, giving it a specialized role in biomedical research. Its established reputation and diverse client base support resilient service revenue, while strategic acquisitions expand its capabilities. Strong operating cash flow also provides flexibility to invest in future growth and innovation.
